Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM)

被引：2

作者：

Burns, Ethan A. ^{[1
]}

Ensor, Joe E. ^{[2
]}

Anand, Kartik ^{[3
]}

Gentille, Cesar ^{[4
]}

Guerrero, Carlo ^{[1
]}

Kieser, Ryan B. ^{[1
]}

Umoru, Godsfavor ^{[5
]}

Shah, Shilpan S. ^{[1
]}

Petkova, Jenny H. ^{[6
]}

Ganguly, Siddhartha ^{[6
,7
]}

Rice, Lawrence ^{[8
]}

Pingali, Sai Ravi Kiran ^{[1
]}

机构：

[1] Houston Methodist Canc Ctr, Houston, TX USA

[2] Houston Methodist Res Inst, Houston, TX USA

[3] Callahan Canc Ctr, Great Plains Hlth, North Platte, NE USA

[4] Stanford Univ, Sch Med, Div Blood & Marrow Transplantat & Cellular Therap, Stanford, CA 94305 USA

[5] Houston Methodist Hosp, Dept Pharm, Houston, TX 77030 USA

[6] Houston Methodist Hosp, Houston, TX 77030 USA

[7] Ctr Canc, Houston, TX USA

[8] Houston Methodist Hosp, Dept Med, Weill Cornell Med Collage, Houston, TX 77030 USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-152068

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4740

引用

页数：4

共 50 条

[41] Clinical Characteristics and Transfusion Management of Patients Diagnosed of Multiple Myeloma Receiving Daratumumab: Experience of a Single Centre
Arnao, Mario
Solves, Pilar
Blanco, Albert
Dominguez, Lara
Gomez, Ines
Andreu, Rafa
Romero, Samuel
Jarque, Isidro
Carpio, Nelly
Sanz, Guillermo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E152 - E153
[42] Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
Mian, Hira
Eisfeld, Christine
Venner, Christopher P.
Masih-Khan, Esther
Kardjadj, Moustafa
Jimenez-Zepeda, Victor H.
Khandanpour, Cyrus
Lenz, Georg
McCurdy, Arleigh
Sebag, Michael
Song, Kevin
LeBlanc, Richard
White, Darrell
Stakiw, Julie
Reiman, Anthony
Louzada, Martha
Aslam, Muhammad
Kotb, Rami
Gul, Engin
Reece, Donna
FRONTIERS IN ONCOLOGY, 2022, 12
[43] Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM).
Yarlagadda, Lakshmi
Gundarlapalli, Sravani
Parikh, Richa
Kottarathara, Mathew
Ogunsesan, Yetunde
Hoque, Shadiqul
Mitma, Angel
Bailey, Clyde
Hill, Kerri
Thanendrarajan, Sharmilan
Grazziutti, Monica
Mohan, Meera
Zangari, Maurizio
Van Rhee, Frits
Tricot, Guido
Schinke, Carolina D.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[44] An open-label, multicenter, phase Ib study of daratumumab in combination with backbone regimens in patients with multiple myeloma
Comenzo, Raymond
Moreau, Philippe
Mateos, Maria-Victoria
Blade, Joan
Benboubker, Lotfi
de la Rubia, Javier
Facon, Thierry
Fay, Joseph
Qin, Xiang
Masterson, Tara
Schecter, Jordan
Ahmadi, Tahamtan
San-Miguel, Jesus
CANCER RESEARCH, 2015, 75
[45] Response to daratumumab-retreatment in patients with multiple myeloma
Souren, Laura
Ihorst, Gabriele
Greil, Christine
Engelhardt, Monika
Waesch, Ralph
ANNALS OF HEMATOLOGY, 2024, : 1059 - 1067
[46] Use of Daratumumab in Patients With Previously Treated Multiple Myeloma
Patel, Ashwin P.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14)
[47] Daratumumab reactivates resolved HBV in patients with multiple myeloma
Reactions Weekly, 2021, 1852 (1) : 10 - 10
[48] ACCELERATED INFUSION OF DARATUMUMAB IS SAFE IN MULTIPLE MYELOMA PATIENTS
Jak, M.
Oostvogels, R.
Minnema, M. C.
HAEMATOLOGICA, 2018, 103 : 20 - 20
[49] DARATUMUMAB INFUSION IN 90 MINUTES IN PATIENTS WITH MULTIPLE MYELOMA
Alfayate, Lobo Ana
Inigo, Rodriguez Maria Belen
Cubillas, Garcia De la Torre Damian
Menendez, Cuevas Marina
Colas, Lahuerta Blanca
Calo, Perez Aida
Gomez, Alvarez Miguel
Estival, Monteliu Pablo
Escribano, Serrat Silvia
Gulino, Martin Horacio
Medina, Salazar Sissy Fiorella
Bolanos, Calderon Estefania
Perez, Lopez Cristina
Pena, Cortijo Ascension
Polo, Zarzuela Marta
Mateo, Morales Marta
Benavente, Cuesta Celina Maria
Daorta, Null Melisa Almendra
Moreno, Paredes Nahir Daniela
HAEMATOLOGICA, 2020, 105 : 363 - 364
[50] Daratumumab for the Treatment of Multiple Myeloma
Plesner, Torben
Krejcik, Jakub
FRONTIERS IN IMMUNOLOGY, 2018, 9

← 1 2 3 4 5 →